Skip to main content
Clinical Trials/NCT01552876
NCT01552876
Completed
Not Applicable

Comparative Clinical Evaluation of Soft Toric Lens Designs

Johnson & Johnson Vision Care, Inc.0 sites42 target enrollmentFebruary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Astigmatism
Sponsor
Johnson & Johnson Vision Care, Inc.
Enrollment
42
Primary Endpoint
Phase I: Absolute Lens Rotation
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study is evaluating the initial fit of toric contact lenses.

Registry
clinicaltrials.gov
Start Date
February 2012
End Date
April 2012
Last Updated
7 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Be greater than or equal to 18 years old.
  • Read, understand, and sign written Statement of Informed Consent.
  • Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Be existing soft contact lens wearers (no extended wear in the last 3 months, but silicone hydrogels in daily wear are allowed).
  • Require a visual correction in both eyes (monovision allowed but no monofit).
  • Have a spherical contact lens requirement in the range -0.50D to -6.00D.
  • Have astigmatism of between -0.50 and -2.00DC in both eyes.
  • Monocular distance visual acuity correctable to 6/9 (0.2 logMAR) or better in each eye with best sphero-cylindrical refraction.
  • Have normal eyes with no evidence of any ocular abnormality or disease. For the purposes of this study a normal eye is defined as one having: Clear cornea, No anterior segment disorder, No clinically significant slit lamp findings (i.e. oedema, staining, scarring, vascularisation, infiltrates or abnormal opacities), No other active ocular disease or recent surgery

Exclusion Criteria

  • Having worn RGP contact lenses within the last 30 days or PMMA contact lenses within the last 3 months.
  • Clinically significant corneal oedema, corneal vascularisation, corneal staining, tarsal abnormalities, bulbar injection or any other abnormality of the cornea that would contraindicate contact lens wear.
  • Extended lens wear in last 3 months.
  • Any systemic or topical medications that will in the investigator's opinion affect ocular physiology or contact lens performance.
  • Any systemic disease affecting ocular health.
  • Abnormal lacrimal secretions.
  • Keratoconus or other corneal irregularity.
  • Pregnancy, lactating or planning a pregnancy at the time of enrolment.
  • Participation in any concurrent clinical trial.
  • Any previous anterior ocular surgery.

Outcomes

Primary Outcomes

Phase I: Absolute Lens Rotation

Time Frame: 3 min after lens insertion during Phase I

Lens orientation position as assessed on a scale of 0-180 on both eyes.

Secondary Outcomes

  • Phase I: Time to Lens Settling(5 minutes after lens insertion during Phase I)
  • Phase I: Number of Blinks Until Settled(Baseline to 5 minutes during Phase I)

Similar Trials